Cetuximab
What's New
Last Posted: Oct 19, 2023
- Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada.
Reka E Pataky et al. Pharmacoecon Open 2023 - A Cost-effectiveness Analysis of Adding Cetuximab to the First-line Treatment of Metastatic Colorectal Carcinoma in Iran; Considering Genetic Screening for Precision Medicine.
Yousefi Nazila et al. Journal of gastrointestinal cancer 2023 - A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab.
Tao Huimin et al. Journal of gastrointestinal oncology 2023 13(6) 3009-3024 - Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
R Yaeger et al, NEJM, December 21, 2022 - Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China.
Li Jun et al. The Journal of international medical research 2021 49(11) 3000605211061040 - Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.
Jensen Benny V et al. International journal of cancer 2020 Dec - Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Fisher Julie G et al. Targeted oncology 2020 Oct - Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
Summers Matthew G et al. European journal of cancer (Oxford, England : 1990) 2020 12456-63 - Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Lenz Heinz-Josef et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 37(22) 1876-1885 - Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy.
Freml Jared et al. Personalized medicine 2020 Apr
More
About PGx PHGKB
PGx PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to medications....more
Content Summary
Common PGx Related Topics
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 27, 2024
- Content source: